BioNTech to close sites in Germany, Singapore affecting 1,860 staff

BioNTech plans to close sites affecting up to 1,860 jobs and authorized up to $1 billion in share buybacks after two co-founders quit the COVID-19 vaccine maker. The restructuring points to operational pressure and governance disruption, partly offset by the capital return announcement. The news is likely to weigh on sentiment for the stock, though it is not sector-wide.

Analysis

BioNTech plans to close sites affecting up to 1,860 jobs and authorized up to $1 billion in share buybacks after two co-founders quit the COVID-19 vaccine maker. The restructuring points to operational pressure and governance disruption, partly offset by the capital return announcement. The news is likely to weigh on sentiment for the stock, though it is not sector-wide.